Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema

Psoriasis is a chronic inflammatory disease which mostly affects skin. Tildrakizumab is a specific anti-interleukin -23p19 monoclonal antibody approved for the treatment of plaque psoriasis in adults. Herein, we report about a patient who came to our attention for a moderate-to-severe plaque psorias...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernardini, Nicoletta, Skroza, Nevena, Rossi, Giovanni, Mambrin, Alessandra, Tolino, Ersilia, Marraffa, Federica, Caviglia, Martina, Guardo, Antonio Di, Volpe, Salvatore, Proietti, Ilaria, Potenza, Concetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724640/
https://www.ncbi.nlm.nih.gov/pubmed/36483227
http://dx.doi.org/10.4081/dr.2022.9447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724640/
https://www.ncbi.nlm.nih.gov/pubmed/36483227
http://dx.doi.org/10.4081/dr.2022.9447

Ejemplares similares